Association of antibiotic exposure with survival in patients with extensive‐stage small cell lung cancer receiving immune checkpoint inhibitor therapy

Association of antibiotic exposure with survival in patients with extensive‐stage small cell lung cancer receiving immune checkpoint inhibitor therapy

Abstract Background Immune checkpoint inhibitors (ICIs) have dramatically shifted the therapeutic paradigm of extensive‐stage small cell lung cancer (ES‐SCLC). Antibiotic (ATB) exposure before or during ICI therapy can harm the integrity of the gut microbiome and lead to intestinal dysbiosis, which...

Full description

Bibliographic Details
Main Authors:	Jiaqi Zhong, Dali Xiong, Yu Liu, Shuanghu Yuan
Format:	Article
Language:	English
Published:	Wiley 2024-01-01
Series:	Thoracic Cancer
Subjects:	antibiotic extensive‐stage small cell lung cancer gut microbiome immune checkpoint inhibitor
Online Access:	https://doi.org/10.1111/1759-7714.15172

Similar Items

The microbial metabolite desaminotyrosine enhances T-cell priming and cancer immunotherapy with immune checkpoint inhibitorsResearch in context
by: Laura Joachim, et al.
Published: (2023-11-01)

Antibiotic therapy and outcome from immune-checkpoint inhibitors
by: David J. Pinato, et al.
Published: (2019-11-01)

Impact of gut-microbiome altering drugs and fecal microbiota transplant on the efficacy and toxicity of immune checkpoint inhibitors: A systematic review
by: Manish D. Angrish, et al.
Published: (2022-07-01)

Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications
by: Daniel Spakowicz, et al.
Published: (2020-05-01)

Association Between Antibiotic and Outcomes of Chemoimmunotherapy for Extensive‐Stage Small Cell Lung Cancer: A Multicenter Retrospective Study of 132 Patients
by: Fang Deng, et al.
Published: (2025-01-01)

Interaction between gut microbiota and immune checkpoint inhibitor-related colitis
by: Guanzhou Zhou, et al.
Published: (2022-10-01)

Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis
by: Hamzah Abu-Sbeih, et al.
Published: (2019-09-01)

An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma
by: Shen YC, et al.
Published: (2021-07-01)

The effect of antibiotics on the clinical outcomes of patients with solid cancers undergoing immune checkpoint inhibitor treatment: a retrospective study
by: Hyunho Kim, et al.
Published: (2019-11-01)

Research Progress on Effects of Gut Microbiome on Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer
by: WANG Yijie, et al.
Published: (2022-11-01)

Gut microbiome in modulating immune checkpoint inhibitors
by: Xiang Li, et al.
Published: (2022-08-01)

Synchronous Oligometastasis and Oligoprogression as a Prognostic Marker in Patients With Extensive-Stage SCLC Treated With a Combination of Immune-Checkpoint Inhibitor and Chemotherapy (HOT2301)
by: Kana Hashimoto, MD, et al.
Published: (2024-11-01)

Use of antibiotics is associated with worse clinical outcomes in patients with cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis
by: Maria Tsikala-Vafea, et al.
Published: (2021-05-01)

Outcome of immune checkpoint inhibitors in patients with extensive-stage small-cell lung cancer and brain metastases
by: Chunyu Wang, et al.
Published: (2023-05-01)

Combination therapy using low‐dose anlotinib and immune checkpoint inhibitors for extensive‐stage small cell lung cancer
by: Han Li, et al.
Published: (2024-12-01)

Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors
by: Arielle Elkrief, et al.
Published: (2019-04-01)

Understanding the role of the gut microbiome in solid tumor responses to immune checkpoint inhibitors for personalized therapeutic strategies: a review
by: Mi Young Lim, et al.
Published: (2025-01-01)

The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors
by: Jiaxin Zhou, et al.
Published: (2022-07-01)

Analysis of prognostic factors affecting immune checkpoint inhibitor therapy in tumor patients exposed to antibiotics
by: Qian Chen, et al.
Published: (2023-07-01)

Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma
by: Petros Fessas, et al.
Published: (2021-10-01)

The association between antibiotic use and outcomes of HCC patients treated with immune checkpoint inhibitors
by: Lilong Zhang, et al.
Published: (2022-08-01)

Faecalibacterium prausnitzii strain EXL01 boosts efficacy of immune checkpoint inhibitors
by: Marius Bredon, et al.
Published: (2024-12-01)

Impact of antibiotics on the efficacy of immune checkpoint inhibitors in the treatment of primary liver cancer
by: Jia-Ren Wang, et al.
Published: (2022-09-01)

First-Line Treatments for Extensive-Stage Small-Cell Lung Cancer With Immune Checkpoint Inhibitors Plus Chemotherapy: A Network Meta-Analysis and Cost-Effectiveness Analysis
by: Shuo Kang, et al.
Published: (2022-01-01)

Assessing the role of colonic and other anatomical sites uptake by [18F]FDG‐PET/CT and immune‐inflammatory peripheral blood indexes in patients with advanced non‐small cell lung cancer treated with first‐line immune checkpoint inhibitors
by: Alessio Rizzo, et al.
Published: (2023-08-01)

Are tumor-associated carbohydrates the missing link between the gut microbiome and response to immune checkpoint inhibitor treatment in cancer?
by: Zoltan Szallasi, et al.
Published: (2024-12-01)

Role of gut microbiota in regulating immune checkpoint inhibitor therapy for glioblastoma
by: Hao Zhang, et al.
Published: (2024-06-01)

Gut microbiota and clinical response to immune checkpoint inhibitor therapy in patients with advanced cancer
by: John Wen-Cheng Chang, et al.
Published: (2024-10-01)

Impact of probiotics use on clinical outcomes of immune checkpoint inhibitors therapy in cancer patients
by: Luying Wan, et al.
Published: (2023-01-01)

Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma
by: David J. Pinato, et al.
Published: (2023-06-01)

Efficacy and safety of immune checkpoint inhibitors combined with chemotherapy as first-line treatment for extensive-stage small cell lung cancer: a meta-analysis based on mixed-effect models
by: Jianqing Zheng, et al.
Published: (2023-07-01)

Perspective on the Role of Gut Microbiome in the Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors
by: Ludovico Abenavoli, et al.
Published: (2023-08-01)

Impact of cannabinoids on cancer outcomes in patients receiving immune checkpoint inhibitor immunotherapy
by: MariaLuisa Vigano, et al.
Published: (2025-03-01)

Effects of Concomitant Antibiotics Use on Immune Checkpoint Inhibitor Efficacy in Cancer Patients
by: Shuai Jiang, et al.
Published: (2022-02-01)

The Role of the Lymphocyte Functional Crosstalk and Regulation in the Context of Checkpoint Inhibitor Treatment—Review
by: Barbara Seliger
Published: (2019-09-01)

Recent Advances in Immune Checkpoint Inhibitor-associated Pneumonitis
by: CHEN Shuangqing, et al.
Published: (2022-10-01)

The Emerging Role of the Gut Microbiome in the Cancer Response to Immune Checkpoint Inhibitors: A Narrative Review
by: Ghada Araji, et al.
Published: (2022-02-01)

Peptide and peptide-inspired checkpoint inhibitors: Protein fragments to cancer immunotherapy
by: Pottayil G. Sasikumar, et al.
Published: (2020-12-01)

Is the survival of patients treated with ipilimumab affected by antibiotics? An analysis of 1585 patients from the French National hospital discharge summary database (PMSI)
by: Pierre-Yves Cren, et al.
Published: (2020-01-01)

Concomitant medications and immune checkpoint inhibitor therapy for cancer: causation or association?
by: Nadiya Hussain, et al.
Published: (2021-01-01)